Translational Control of Immune Evasion in Cancer
Open Access
- 1 July 2021
- journal article
- editorial
- Published by Elsevier in Trends in Cancer
- Vol. 7 (7) , 580-582
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (RP200327, RP190610, I-1881, R01 CA207763, P50CA70907)
- Welch Foundation (RP200327, RP190610, I-1881, R01 CA207763, P50CA70907)
- Cancer Prevention and Research Institute of Texas (RP200327, RP190610, I-1881, R01 CA207763, P50CA70907)
- Comprehensive Cancer Center, University of Chicago Medical Center (RP200327, RP190610, I-1881, R01 CA207763, P50CA70907)
This publication has 15 references indexed in Scilit:
- Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanomaNature Medicine, 2018
- Translational Control in CancerCold Spring Harbor Perspectives in Biology, 2018
- Development of a stress response therapy targeting aggressive prostate cancerScience Translational Medicine, 2018
- Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophilsProceedings of the National Academy of Sciences, 2018
- Impact of oncogenic pathways on evasion of antitumour immune responsesNature Reviews Cancer, 2018
- Oxygen-Sensitive Remodeling of Central Carbon Metabolism by Archaic eIF5BCell Reports, 2018
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Translation from unconventional 5′ start sites drives tumour initiationNature, 2017
- Translational control by 5′-untranslated regions of eukaryotic mRNAsScience, 2016
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancersNature, 2016